We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    attain stability quad
Previous Study | Return to List | Next Study

Attain Stability™ Quad Clinical Study

This study is enrolling participants by invitation only.
Sponsor:
ClinicalTrials.gov Identifier:
NCT03099655
First Posted: April 4, 2017
Last Update Posted: July 31, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Medtronic Cardiac Rhythm and Heart Failure
March 14, 2017
April 4, 2017
July 31, 2017
July 7, 2017
March 2019   (Final data collection date for primary outcome measure)
  • Lead complication-free rate at 6 months [ Time Frame: Implant to 6 months post-implant ]
    Subjects free of Model 4798 lead-related complications at 6 months post-implant
  • Proportion of subjects with at least one vector having PCT ≤2.5 V at 0.5 ms pulse width and absence of Phrenic Nerve Stimulation (PNS) [ Time Frame: Implant to 6 months post-implant ]
    The Model 4798 LV lead has sixteen (16) programmable pacing vectors. The endpoint for the primary efficacy objective is whether or not there is at least one Model 4798 LV lead pacing vector with pacing capture voltage thresholds less than or equal to 2.5V.
  • Proportion of subjects with at least one extra vector having PCT ≤ 4.0V at 0.5 ms pulse width and absence of Phrenic Nerve Stimulation (PNS) [ Time Frame: Implant to 6 months post-implant ]
    The co-primary efficacy endpoint is whether or not a second Model 4798 lead configuration has a pacing capture threshold less than or equal to 4V, excluding the pacing vector that is already counted to the primary efficacy.
Same as current
Complete list of historical versions of study NCT03099655 on ClinicalTrials.gov Archive Site
  • Implant Success [ Time Frame: Intraoperative ]
    Number of Attain Stability leads successfully implanted subjects divided by number of subjects undergo Attain Stability lead implant procedure
  • Implant Duration [ Time Frame: Intraoperative ]
    Summary statistics including mean and standard deviation will be obtained for implant duration (minutes) for each successful implant procedure.
  • LV Pacing Capture Threshold (PCT) at 6 months [ Time Frame: Implant to 6 months post-implant ]
    Summary statistics including mean and standard deviation will be obtained for PCT (volt) measured at 6-month post implant visit for each successful implanted subject
  • LV Impedance at 6 months [ Time Frame: Implant to 6 months ]
    Summary statistics including mean and standard deviation will be obtained for Pacing Impedance (Ohm) measured at 6-month post implant visit for each successful implanted subject
  • Post Implant lead failure rate [ Time Frame: Implant to 6 months ]
    Number of subjects with a given complication from implant through 6 months (183 days) by total number of subjects undergo Attain Stability implant procedure
Same as current
Not Provided
Not Provided
 
Attain Stability™ Quad Clinical Study
Attain Stability™ Quad Clinical Study
The purpose of this clinical study is to evaluate the safety and efficacy of the Attain Stability Quadripolar MRI SureScan Left Ventricular (LV) lead (Model 4798).

The Attain Stability Quad Clinical Study is a prospective, non-randomized, multi-site, global, investigational Device Exemption (IDE), interventional clinical study. The purpose of this clinical study is to evaluate the safety and efficacy of the Attain Stability™ Quad MRI SureScan LV Lead (Model 4798). This will be assessed through a primary safety and primary efficacy endpoints.

All subjects included in the study will be implanted with a Medtronic market released de novo CRT-P or CRT-D device, compatible market released Medtronic RA and Medtronic RV leads and an Attain Stability Quad MRI SureScan LV Lead (Model 4798).

Up to 471 subjects will be enrolled into the study and up to 471 Attain Stability Quad MRI SureScan LV Lead (Model 4798) implanted, to ensure a minimum effective sample size of 400 Model 4798 leads implanted with 6 months post implant follow up visits (assuming 15% attrition) at up to 56 sites worldwide.

Interventional
Not Provided
Intervention Model: Single Group Assignment
Intervention Model Description:
The Medtronic Attain Stability Quad MRI SureScan (Model 4798) is a steroid-eluting, quadripolar electrode, transvenous, over-the-wire (OTW), IS4-LLLL compatible, active fixation, cardiac vein pacing LV lead. This lead is similar to the Attain Performa family of quadripolar leads (Models 4298, 4398, and 4598) but also has a side helix for active fixation which is similar to the Attain Stability bipolar lead (Model 20066/4796) (available outside of the United States).
Masking: None (Open Label)
Primary Purpose: Treatment
Heart Failure
Device: Attain Stability Quad Left Ventricular Pacing Lead
cardiac stimulation
Other Name: 4798 Lead
Experimental: Attain Stability Quad Lead
Attain Stability Quad Lead (Model 4798) - Single arm study.
Intervention: Device: Attain Stability Quad Left Ventricular Pacing Lead
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Enrolling by invitation
471
October 2019
March 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient meets CRT implant criteria as determined by local regulatory and/or hospital policy (i.e. US subjects should meet CRT device indications per the HRS/ACC/AHA guidelines)
  • Patient (or legally authorized representative) has signed and dated the study-specific Informed Consent Form
  • Patient is 18 years of age or older, or is of legal age to give informed consent per local and national law
  • Patient is expected to remain available for follow-up visits

Exclusion Criteria:

  • Patient has had a previous unsuccessful LV lead implant attempt
  • Patient has a previous CRT system or LV lead implanted (for example, transvenous or epicardial)
  • Patient is currently implanted with a recalled (i.e. market-withdrawn, recalled or safety alert) RA and/or RV lead
  • Patient has known coronary venous vasculature that is inadequate for lead placement
  • Patient has unstable angina pectoris or has had an acute myocardial infarction (MI) within the past 30 days
  • Patient has had a coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) within the past 90 days
  • Patient has contraindications for standard transvenous cardiac pacing (e.g., mechanical right heart valve)
  • Patient has had a heart transplant (patients waiting for heart transplants are allowed in the study)
  • Patient has known renal insufficiency that would prevent them from receiving an occlusive venogram during the implant procedure
  • Patient is contraindicated for <1mg dexamethasone acetate
  • Patient is enrolled in any concurrent drug and/or device study that may confound the results of this study
  • Patient has a terminal illness and is not expected to survive more than six months
  • Patient meets exclusion criteria required by local law (e.g. age, pregnancy, breast feeding, etc.)
  • Patient is unable to tolerate an urgent thoracotomy
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada,   Germany,   Hong Kong,   Italy,   Malaysia,   Netherlands,   Norway,   Spain,   Sweden,   United States
 
 
NCT03099655
Attain Stability Quad
No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No
Plan to Share IPD: No
Medtronic Cardiac Rhythm and Heart Failure
Medtronic Cardiac Rhythm and Heart Failure
Not Provided
Not Provided
Medtronic Cardiac Rhythm and Heart Failure
July 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP